These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11016001)

  • 1. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].
    Fujii M; Kanke M; Arai Y; Kawai S; Enomoto H; Inaba H; Taguchi T; Tsukuda M
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1557-63. PubMed ID: 11016001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
    Kimura E; Niimi S; Watanabe A; Akiyama M; Tanaka T
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):477-81. PubMed ID: 8678501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
    Kimura E; Niimi S; Watanabe A; Tanaka T
    Gan To Kagaku Ryoho; 1997 May; 24(7):855-9. PubMed ID: 9170525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
    Tanigaki Y; Mikami Y; Matsuda H; Horiuchi C; Taguchi T; Yoshida T; Ishitoya J; Katori H; Ikeda Y; Tsukuda M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2091-5. PubMed ID: 16352934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
    Hayakawa T; Sato M; Konaka M; Makino A; Hirohata T; Totsu S; Wada Y; Sato H; Inotsume N; Fujita A; Sekine K
    Gan To Kagaku Ryoho; 2006 May; 33(5):633-8. PubMed ID: 16685162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
    Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
    Tsukuda M; Kohno H; Enomoto H; Kawai S; Yago T; Matsuda H; Ikema Y; Makino Y; Kubota A; Furukawa M
    Gan To Kagaku Ryoho; 1995 Sep; 22(10):1377-82. PubMed ID: 7668873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
    Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.
    Münstedt K; Müller H; Blauth-Eckmeyer E; Stenger K; Zygmunt M; Vahrson H
    Br J Cancer; 1999 Feb; 79(3-4):637-9. PubMed ID: 10027342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.